ClinConnect ClinConnect Logo
Search / Trial NCT01542801

Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

Launched by KOREA UNIVERSITY · Mar 1, 2012

Trial Information

Current as of May 21, 2025

Completed

Keywords

Effect Of Preventive Antibiotics

ClinConnect Summary

Spontaneous bacterial peritonitis (SBP) is one of the most serious complication of liver cirrhosis.

The short term mortality reaches 20-30% mainly due to sepsis, hepatorenal syndrome, and liver failure. In addition, patients who suffered SBP show poor prognosis with 1 year-mortality of 50-70%. The high recurrence rate is also problematic. Therefore appropriate prevention of SBP is critically needed to improve survival as well as quality of life.

Selective intestinal decontamination (SID) is eradicating gram negative bacterial in the gut lumen, and effectively prevent development of SBP. P...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age between 20-75 years old
  • Liver cirrhosis with ascites
  • Ascitic polymorphonucleated cells (PMN) count \< 250/mm3
  • Ascitic protein \<= 1.5 g/dL or History of SBP
  • Exclusion Criteria:
  • Incompatibility with inclusion criteria
  • Hypersensitivity or intolerability with quinolones
  • Hepatocellular carcinoma beyond Milan Criteria
  • Hepatic encephalopathy over stage 2
  • History of treatment with antibiotics within 2 weeks of enrollment
  • HIV infection
  • Untreated malignancy
  • Women with child-bearing age not willing to use effective contraception.
  • Pregnant or breast feeding women
  • Not able to give informed consents

About Korea University

Korea University is a prestigious academic institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Korea University leverages its extensive resources and expertise to conduct innovative studies aimed at enhancing healthcare outcomes. The university fosters collaboration among leading researchers, medical professionals, and industry partners to drive the development of new therapies and interventions. With a focus on ethical standards and patient safety, Korea University is dedicated to contributing valuable insights to the scientific community and improving the quality of life for patients both locally and globally.

Locations

Seoul, , Korea, Republic Of

Ansan, Gyeonggi Do, Korea, Republic Of

Bucheon, , Korea, Republic Of

Cheonan, , Korea, Republic Of

Daegu, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Soon Ho Um, M.D., Ph.D.

Principal Investigator

Korea University Anam Hospital

Hyung Joon Yim, M.D., Ph.D.

Study Director

Korea University Ansan Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials